SDAI Limited
Singapore Registration No. 201107179D
Level 39 Marina Bay Financial Centre Tower
2, 10 Marina Boulevard, Singapore 018983
https://www.sdai.com.sg/

NEWS RELEASE

SDAI Establishes Scientific Board to Advance Its Longevity-focused Biotechnology Strategy

- Five-member panel chaired by Professor Brian Kennedy to guide scientific strategy, research translation and collaboration

SINGAPORE, 4 November 2026 – SDAI Limited ("**SDAI**" or the "**Company**", and together with its subsidiaries, the "**Group**") has established a scientific board which comprises five members ("**Scientific Board**"), chaired by Professor Brian Kennedy, to guide its scientific strategy and support its transformation into a longevity-focused biotechnology company.

The Scientific Board will provide advisory input to the Group on research priorities, the evaluation and commercial translation of emerging science, and collaboration with research institutions and industry partners. Its establishment builds on the Group's diversification into biotechnology encompassing the development, distribution and provision of anti-ageing and longevity-focused healthcare products and services.[1]

Members of the Scientific Board

The Scientific Board comprises five members with expertise spanning ageing biology, cell biology, drug discovery and the translation of scientific research into potential health solutions[2]:

1. Professor Brian Kennedy, Chief Scientist of the "Maximising Healthy and Successful Longevity" grand challenge, which was launched by the National Research Foundation, in partnership with the Ministry of Health of Singapore in May 2026 under Singapore's S$37 billion five-year Research, Innovation and Enterprise 2030 plan, and Distinguished Professor of Biochemistry and Physiology at the Yong Loo Lin School of Medicine, National University of Singapore ("**NUS**"),

[1] Approved by shareholders of the Company ("**Shareholders**") at an Extraordinary General Meeting of the Company held on 30 April 2026.
[2] Shareholders should note that information relating to the biodata of the members of the Scientific Board in this section and elsewhere in this announcement was provided by the respective members. The Company and the Directors have not independently verified the accuracy and correctness of such information herein.

who will chair the Scientific Board. He received his PhD in Biology from the Massachusetts Institute of Technology, Cambridge, MA, USA;

2. Professor Liou Yih-Cherng (刘益成), Associate Professor and Research Lead (Cell, Molecular and Developmental Biology Group) in the Department of Biological Sciences, NUS. He obtained his PhD in Biochemistry from Queen's University in Canada;

3. Professor Li Rong (李荣), Platform Expert (Metabolomics and Lipidomics) at the Institute of Metabolism and Integrative Biology, Fudan University. He obtained his PhD in Pharmacology from Yong Loo Lin School of Medicine, NUS;

4. Professor Victor Yu (俞振纲), Principal Investigator at Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou University. He obtained his PhD in Pharmaceutical Chemistry from the University of California, San Francisco; and

5. Dr He Chong (贺冲), Principal Investigator at the Asian Academy of Anti-Aging and Translational Medicine. She obtained her PhD in Biochemistry from Peking University.

Role of the Scientific Board

The role of SDAI's Scientific Board is as follows:

1. **Scientific Strategy & Corporate Development**
   Provide strategic scientific guidance to support SDAI's transformation into a longevity-focused company, shaping its long-term direction in healthy ageing, biological age management and science-driven innovation.

2. **Scientific Innovation & Commercial Translation**
   Guide the evaluation and translation of longevity research into scientifically grounded products, technologies and health solutions, supporting SDAI's development of a credible and sustainable longevity business.

3. **Global Scientific Partnerships & Long-Term Value Creation**
   Strengthen SDAI's connections with leading scientists, research institutions and global innovation networks, fostering scientific credibility, strategic partnerships and long-term value creation.

Madam Hao Dongting (郝东亭), Executive Chairperson of the Company, commented, *"The establishment of our Scientific Board is an important step in strengthening the scientific foundations of SDAI's biotechnology strategy. Chaired by Professor Brian*

Kennedy, the Scientific Board brings together expertise that will help us formulate research strategies, sharpen our development priorities and build meaningful research collaborations. With the Scientific Board's guidance, we aim to develop a differentiated portfolio grounded in scientific evidence and translate relevant research into practical, accessible and scalable consumer offerings. The Scientific Board will also play a key role in the transformation of SDAI into a longevity-focused biotechnology company with a sustainable business model, thereby allowing us to apply for a resumption of trading in due course."

Asia-Pacific's anti-ageing market is expected to reach US$20.6 billion in 2025 and is forecast to grow at a compounded annual growth rate of 8.0% to reach US$38.1 billion by 2033. The increasing need for anti-ageing products across all demographic groups can be attributed to various factors, including a continued ageing population and rising awareness, according to Cognitive Market Research and Consulting.[3]

In Singapore, the research and innovation ecosystem is supported by the Government's S$37 billion Research, Innovation and Enterprise 2030 ("**RIE2030**") research plan, covering the five years from April 2026. As part of RIE2030, the National Research Foundation, in partnership with the Ministry of Health, announced the Grand Challenge on "Maximising Healthy and Successful Longevity" in May 2026, with the Government committing S$350 million to the initiative. The Grand Challenge focuses on brain health, physical function and socio-environmental innovations to support healthy longevity.

The establishment of the Scientific Board marks a further step in implementing the Group's biotechnology diversification strategy. Building on its three business segments involving skin anti-ageing, anti-ageing supplements and solutions and mugwort-based moxibustion health management, the Group aims to strengthen the scientific evaluation of its development initiatives and identify opportunities to translate relevant research into products and services tailored to Asian consumers.

With its Scientific Board in place, the Group intends to deepen research collaborations and pursue the disciplined development and commercialisation of its longevity-focused portfolio. While the transformation remains at an early stage, the Company believes that strengthening its scientific capabilities will support differentiated offerings, new revenue opportunities and sustainable long-term value for Shareholders.

End.

[3] https://www.cognitivemarketresearch.com/regional-analysis/asia-pacific-anti-aging-products-market-report

About SDAI Limited

Listed on the Catalist board of the Singapore Exchange since 22 July 2011, **SDAI Limited** (the "**Company**", and together with its subsidiaries the "**Group**") is a biotechnology company focused on anti-ageing, longevity and biological age management solutions. As announced by the Company on 8 May 2026, the Group entered into a strategic cooperation agreement with LiveBeyond Pte. Ltd. to explore collaboration opportunities in the areas of anti-ageing biotechnology, healthcare related products and services, as well as research and development initiatives.

The Company's other products and business initiatives include, amongst others:

- In June 2026, the Group entered into a supplier agreement with a biotechnology company incorporated in the United States of America for the manufacture and supply of **Calcium Alpha-Ketoglutarate supplements**.

- **Bluecode Biotech B-III skincare series ("B-III Series")**, a plant stem cell-based range developed in-house. The B-III Series combines advanced bioengineering with next-generation plant stem cell technology for anti-ageing and regenerative skincare.

- In January 2026, the Group entered into a joint venture with Hubei Qiai Group Co., Ltd. to expand the market for **mugwort and moxibustion-related products** across the ASEAN region.

As the Group shifts its focus to its longevity and healthcare business, it has significantly scaled down its business of distributing high-end kitchen systems and appliances. By continuously engaging with developments in global longevity science and combining them with the health needs and lifestyles of Asian consumers, the Group aims to bring credible and commercially sustainable longevity solutions to markets across Asia.

For more information, visit https://www.sdai.com.sg/

For media enquiries contact	:	Ms Karina Choo / Mr Gerald Woon
Email / Mobile	:	karina@cogentcomms.com / (65) 9107 6991
		woon@cogentcomms.com / (65) 9694 8364

*This press release has been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "**Sponsor**").*

*This press release has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

The contact person for the Sponsor is Ms Yang Zhenni, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.